LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

JNJ

154.71

+0.26%↑

ABBV

166.41

+1.24%↑

Home・Stock List・Merck & Co Inc.

Merck & Co Inc.

Open

131.21 0.28

Buy Sell

Overview

Share price change

24h

Current

Min

130.62

Max

131.31

Key metrics
By Trading Economics
Income	-6B -1.2B
Sales	1.2B 16B
P/E Sector Avg	60.41 23.904
EPS	2.07
Dividend yield	2.531
Profit margin	-8.38
Employees	72,000
EBITDA	11B 7.5B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+5.85 upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.53% 7.76%
Next Earnings	30 Jul 2024
Next Dividend date	8 Jul 2024
Next Ex Dividend date	12 Jun 2024

Market Stats
By TradingEconomics
Market Cap	4.5B 332B
Previous open	130.93
Previous close	131.21

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

130.38 / 131.51 Support & Resistance

Merck & Co Inc. Chart

Related News

26 Mar 2024, 23:51 UTC

Hot Stocks

Stocks to Watch: GameStop, Merck, Bowman Consulting

26 Mar 2024, 21:52 UTC

Major Market Movers

Merck Shares Rise 5% on FDA Approval for Winrevair

25 Apr 2024, 20:03 UTC

Earnings

Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat -- IBD

25 Apr 2024, 10:31 UTC

Earnings

Merck Adjusts FY View To Adj EPS $8.53-Adj EPS $8.65 >MRK

25 Apr 2024, 10:31 UTC

Earnings

Merck Adjusted Expected FY Worldwide Sales Range to $63.1B-$64.3B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Pharmaceutical Sales $14.01B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Pharmaceutical Sales Up 10% >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Keytruda Sales $6.95B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Keytruda Sales Up 20% >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Gardasil/Gardasil 9 Sales $2.25B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Januvia/Janumet Sales $670M >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Adj EPS $2.07 >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Januvia/Janumet Sales Down 24% >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Animal Health Sales Up 1% >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Gardasil/Gardasil 9 Sales Up 14% >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q EPS $1.87 >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Net $4.76B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Animal Health Sales $1.51B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck Sees FY Adj EPS $8.53-Adj EPS $8.65 >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck 1Q Sales $15.8B >MRK

25 Apr 2024, 10:30 UTC

Earnings

Merck Sees FY Rev $63.1B-$64.3B >MRK

25 Apr 2024, 09:20 UTC

Hot Stocks

Stocks to Watch Thursday: Meta, IBM, Anglo American, Microsoft -- WSJ

4 Apr 2024, 05:00 UTC

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

5.85% upside

12 Months Forecast

Average 138.86 USD 5.85%

High 150 USD

Low 104 USD

Based on 16 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Merck & Co Inc. - Dist in the past 3 months.

Technical Score

By Trading Central

130.38 / 131.51Support & Resistance

Recent bullish events outweigh bearish events.

Bullish events outweigh bearish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.